Matching placebo administered by subcutaneous or intravenous injection.

The maximum observed serum concentration of tezepelumab was estimated based on the serum concentrations of tezepelumab using noncompartmental methods.

The concentration of tezepelumab in human serum was measured using a validated enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification of the assay was 10 ng/mL.

The PK parameter AUC0-t was estimated based on the serum concentrations of tezepelumab using noncompartmental methods and the linear/log trapezoidal method. The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/mL.

The PK parameter AUCinf was estimated based on the serum concentrations of tezepelumab using noncompartmental methods and the linear/log trapezoidal method. The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/mL.

Elimination half-life was estimated based on the serum concentrations of tezepelumab using noncompartmental methods based on the terminal phase of the concentration-time profile.

The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/mL.

Tmax was estimated based on the serum concentrations of tezepelumab using noncompartmental methods.

The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/mL.

Cmax was estimated based on the serum concentrations of tezepelumab using noncompartmental methods.

The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/mL.

The PK parameter AUC0-t was estimated based on the serum concentrations of tezepelumab using noncompartmental methods and the linear/log trapezoidal method. The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/mL.

The PK parameter AUCinf was estimated based on the serum concentrations of tezepelumab using noncompartmental methods and the linear/log trapezoidal method. The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/mL.

Elimination half-life was estimated based on the serum concentrations of tezepelumab using noncompartmental methods based on the terminal phase of the concentration-time profile.

The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/mL.

EASI is a tool used to measure the severity of AD. The index involves an assessment of the average intensity of 4 clinical signs (erythema, infiltration/papulation, excoriations, and lichenification) at 4 body areas (head/neck, upper extremities, trunk, lower extremities) assessed on a scale: 0 = none, 1 = mild, 2 = moderate, 3 = severe.

The percent of affected area for each of the 4 body areas is also assessed using the following 6-point scale: 0 = 0%, 1 = < 10%, 2 =10% to 29%, 3 = 30% to 49%, 4 = 50% to 69%, 5 = 70% to 89%, 6 = 90% to 100%. The total score for each body region is obtained by multiplying the sum of the severity scores of the 4 clinical signs by the area score, with adjustment for the proportion of the body region to the whole body.

The sum of the scores for each body region gives the total EASI score, which ranges from 0 to 72, with higher scores indicating greater disease severity.

EASI is a tool used to measure the severity of AD. The index involves an assessment of the average intensity of 4 clinical signs (erythema, infiltration/papulation, excoriations, and lichenification) at 4 body areas (head/neck, upper extremities, trunk, lower extremities) assessed on a scale: 0 = none, 1 = mild, 2 = moderate, 3 = severe.

The percent of affected area for each of the 4 body areas is also assessed using the following 6-point scale: 0 = 0%, 1 = < 10%, 2 =10% to 29%, 3 = 30% to 49%, 4 = 50% to 69%, 5 = 70% to 89%, 6 = 90% to 100%. The total score for each body region is obtained by multiplying the sum of the severity scores of the 4 clinical signs by the area score, with adjustment for the proportion of the body region to the whole body.

The sum of the scores for each body region gives the total EASI score, which ranges from 0 to 72, with higher scores indicating greater disease severity.

EASI is a tool used to measure the severity of AD. The index involves an assessment of the intensity of 4 clinical signs (erythema, infiltration/papulation, excoriations, and lichenification) at 4 body areas (head/neck, upper extremities, trunk, lower extremities) assessed on a scale from 0 (none) to 3 (severe).

The percent affected area for each of the 4 body areas is assessed on a 6-point scale from 0 (0%) to 6 (90% to 100%). The total score for each body region is obtained by multiplying the sum of the severity scores of the 4 clinical signs by the area score, with adjustment for the proportion of the body region to the whole body.

The total EASI score is the sum of the scores for each body region, and ranges from 0 to 72, with higher scores indicating greater disease severity.

Percent change from baseline = [(Post-baseline Value - Baseline Value) / Baseline Value] x 100.

A negative change from baseline indicates improvement.

IGA score is a static 6-point measure of disease activity based on an overall assessment of skin lesions. The IGA was scored on a scale of 0 to 5, where 0 (clear) = no inflammatory signs of AD;

1. (almost clear) = just perceptible erythema and just perceptible papulation/infiltration;
2. (mild) = mild erythema and mild papulation and infiltration;
3. (moderate) = moderate erythema and moderate papulation and infiltration;
4. (severe) = severe disease with severe erythema and severe papulation and infiltration;
5. (very severe) = severe disease with severe erythema and severe papulation and infiltration with oozing/crusting.

A negative change from baseline indicates improvement.

Healthy participants received a single dose of 21 mg tezepelumab administered subcutaneously.

Healthy participants received a single dose of 70 mg tezepelumab administered subcutaneously.

Healthy participants received a single dose of 210 mg tezepelumab administered subcutaneously.

Healthy participants received a single dose of 420 mg tezepelumab administered subcutaneously.

Healthy participants received a single dose of 210 mg tezepelumab administered intravenously.

Healthy participants received a single dose of 700 mg tezepelumab administered intravenously.

Healthy participants received a single dose of placebo to tezepelumab administered subcutaneously or intravenously.

Participants with atopic dermatitis received a single dose of 700 mg tezepelumab administered intravenously.

Participants with atopic dermatitis received a single dose of placebo to tezepelumab administered intravenously.

Total of all reporting groups

The time at which the maximum concentration of tezepelumab was observed was estimated based on the serum concentrations of tezepelumab using noncompartmental methods.

The concentration of tezepelumab in human serum was measured using a validated enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification of the assay was 10 ng/mL.

Participants in Part A who received tezepelumab and had a sufficient number of serum concentration measurements for computing the pharmacokinetic (PK) parameter.

All study samples (tezepelumab and placebo) were tested using an electrochemiluminescence (ECL) based immunoassay to detect and confirm the presence of antibodies capable of binding to tezepelumab. Samples identified as positive in the immunoassay were tested in a receptor-binding ECL-based assay to detect neutralizing or inhibitory effects toward tezepelumab.

The number of participants with positive anti-tezepelumab binding antibodies / neutralizing antibodies at any time post-baseline with a negative or no result at baseline is reported.

All participants who received at least 1 dose of study drug with a postbaseline result.

The maximum observed serum concentration of tezepelumab was estimated based on the serum concentrations of tezepelumab using noncompartmental methods.

The concentration of tezepelumab in human serum was measured using a validated enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification of the assay was 10 ng/mL.

Participants in Part A who received tezepelumab and had a sufficient number of serum concentration measurements for computing the PK parameter.

The PK parameter AUC0-t was estimated based on the serum concentrations of tezepelumab using noncompartmental methods and the linear/log trapezoidal method. The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/mL.

Participants in Part A who received tezepelumab and had a sufficient number of serum concentration measurements for computing the PK parameter.

The PK parameter AUCinf was estimated based on the serum concentrations of tezepelumab using noncompartmental methods and the linear/log trapezoidal method. The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/mL.

Participants in Part A who received tezepelumab and had a sufficient number of serum concentration measurements for computing the PK parameter.

Elimination half-life was estimated based on the serum concentrations of tezepelumab using noncompartmental methods based on the terminal phase of the concentration-time profile.

The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/mL.

Participants in Part A who received tezepelumab and had a sufficient number of serum concentration measurements for computing the PK parameter.

Tmax was estimated based on the serum concentrations of tezepelumab using noncompartmental methods.

The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/mL.

Participants in Part B who received tezepelumab and had a sufficient number of serum concentration measurements for computing the PK parameter.

Cmax was estimated based on the serum concentrations of tezepelumab using noncompartmental methods.

The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/mL.

Participants in Part B who received tezepelumab and had a sufficient number of serum concentration measurements for computing the PK parameter.

The PK parameter AUC0-t was estimated based on the serum concentrations of tezepelumab using noncompartmental methods and the linear/log trapezoidal method. The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/mL.

Participants in Part B who received tezepelumab and had a sufficient number of serum concentration measurements for computing the PK parameter.

The PK parameter AUCinf was estimated based on the serum concentrations of tezepelumab using noncompartmental methods and the linear/log trapezoidal method. The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/mL.

Participants in Part B who received tezepelumab and had a sufficient number of serum concentration measurements for computing the PK parameter.

Elimination half-life was estimated based on the serum concentrations of tezepelumab using noncompartmental methods based on the terminal phase of the concentration-time profile.

The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/mL.

Participants in Part B who received tezepelumab and had a sufficient number of serum concentration measurements for computing the PK parameter.

EASI is a tool used to measure the severity of AD. The index involves an assessment of the average intensity of 4 clinical signs (erythema, infiltration/papulation, excoriations, and lichenification) at 4 body areas (head/neck, upper extremities, trunk, lower extremities) assessed on a scale: 0 = none, 1 = mild, 2 = moderate, 3 = severe.

The percent of affected area for each of the 4 body areas is also assessed using the following 6-point scale: 0 = 0%, 1 = < 10%, 2 =10% to 29%, 3 = 30% to 49%, 4 = 50% to 69%, 5 = 70% to 89%, 6 = 90% to 100%. The total score for each body region is obtained by multiplying the sum of the severity scores of the 4 clinical signs by the area score, with adjustment for the proportion of the body region to the whole body.

The sum of the scores for each body region gives the total EASI score, which ranges from 0 to 72, with higher scores indicating greater disease severity.

All participants in Part B who received at least 1 dose of study drug and with available data at each time point.

EASI is a tool used to measure the severity of AD. The index involves an assessment of the average intensity of 4 clinical signs (erythema, infiltration/papulation, excoriations, and lichenification) at 4 body areas (head/neck, upper extremities, trunk, lower extremities) assessed on a scale: 0 = none, 1 = mild, 2 = moderate, 3 = severe.

The percent of affected area for each of the 4 body areas is also assessed using the following 6-point scale: 0 = 0%, 1 = < 10%, 2 =10% to 29%, 3 = 30% to 49%, 4 = 50% to 69%, 5 = 70% to 89%, 6 = 90% to 100%. The total score for each body region is obtained by multiplying the sum of the severity scores of the 4 clinical signs by the area score, with adjustment for the proportion of the body region to the whole body.

The sum of the scores for each body region gives the total EASI score, which ranges from 0 to 72, with higher scores indicating greater disease severity.

All participants in Part B who received at least 1 dose of study drug and with available data at each time point.

EASI is a tool used to measure the severity of AD. The index involves an assessment of the intensity of 4 clinical signs (erythema, infiltration/papulation, excoriations, and lichenification) at 4 body areas (head/neck, upper extremities, trunk, lower extremities) assessed on a scale from 0 (none) to 3 (severe).

The percent affected area for each of the 4 body areas is assessed on a 6-point scale from 0 (0%) to 6 (90% to 100%). The total score for each body region is obtained by multiplying the sum of the severity scores of the 4 clinical signs by the area score, with adjustment for the proportion of the body region to the whole body.

The total EASI score is the sum of the scores for each body region, and ranges from 0 to 72, with higher scores indicating greater disease severity.

Percent change from baseline = [(Post-baseline Value - Baseline Value) / Baseline Value] x 100.

A negative change from baseline indicates improvement.

All participants in Part B who received at least 1 dose of study drug and with available data at each time point.

IGA score is a static 6-point measure of disease activity based on an overall assessment of skin lesions. The IGA was scored on a scale of 0 to 5, where 0 (clear) = no inflammatory signs of AD;

1. (almost clear) = just perceptible erythema and just perceptible papulation/infiltration;
2. (mild) = mild erythema and mild papulation and infiltration;
3. (moderate) = moderate erythema and moderate papulation and infiltration;
4. (severe) = severe disease with severe erythema and severe papulation and infiltration;
5. (very severe) = severe disease with severe erythema and severe papulation and infiltration with oozing/crusting.

A negative change from baseline indicates improvement.

All participants in Part B who received at least 1 dose of study drug and with available data at each time point.

Healthy participants received a single dose of 7 mg tezepelumab administered subcutaneously.

Healthy participants received a single dose of 21 mg tezepelumab administered subcutaneously.

Healthy participants received a single dose of 70 mg tezepelumab administered subcutaneously.

Healthy participants received a single dose of 210 mg tezepelumab administered subcutaneously.

Healthy participants received a single dose of 420 mg tezepelumab administered subcutaneously.

Healthy participants received a single dose of 210 mg tezepelumab administered intravenously.

Healthy participants received a single dose of 700 mg tezepelumab administered intravenously.

Healthy participants received a single dose of placebo to tezepelumab administered subcutaneously.

Healthy participants received a single dose of placebo to tezepelumab administered intravenously.

Participants with atopic dermatitis received a single dose of 700 mg tezepelumab administered intravenously.

Participants with atopic dermatitis received a single dose of placebo to tezepelumab administered intravenously.